ANDA 62376, held by Bristol. Cefadroxil/Cefadroxil Hemihydrate.
As of Nov 16, 2026, ANDA 62376 (Ultracef), held by Bristol, was not approved, with 0 approved supplements and 0 published complete response letters.
| UltracefEQ 125MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
| UltracefEQ 250MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
| UltracefEQ 500MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters